Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pasithea Therapeutics Corp.KTTA · Entity 7685 | Director | May 01, 2026 | May 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pasithea Therapeutics Corp.
Report date May 01, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2036-04-30 | Direct | 152,783 |
Reported balance
After 2026-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 152,783 · Balance 152,783 F1: The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan).
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dova Pharmaceuticals Inc.
Report date November 12, 2019 · Filed November 12, 2019
Section 16 reporting ended · disclosed 2019-11-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-12 transaction · row 1
1 source rowRow 1 · 2019-11-12 · Disposition to issuer · Disposed 6,901 · Balance 0 F1: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.32 · Expires 2027-05-24 | Direct | 0 |
Reported balance
After 2019-11-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-12 · Disposition to issuer · Disposed 33,000 · Balance 0 F2: This option, which provided for vesting over a period of three years as follows: (i) one-third of the total shares subject to the option shall vest on May 25, 2018, and (ii) 1/36th of total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of 665,940.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.36 · Expires 2029-04-25 | Direct | 0 |
Reported balance
After 2019-11-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-12 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: This option, which provided for vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, was accelerated and canceled in the Merger in exchange for a cash payment of $181,400.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone.
F2: This option, which provided for vesting over a period of three years as follows: (i) one-third of the total shares subject to the option shall vest on May 25, 2018, and (ii) 1/36th of total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of 665,940.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option.
F3: This option, which provided for vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, was accelerated and canceled in the Merger in exchange for a cash payment of $181,400.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option.
LivaNova PLC
Report date June 15, 2022 · Filed June 17, 2022
Section 16 reporting ended · disclosed 2022-06-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 12,617 |
Ending reported balance
After 2022-06-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-06-15 · Exercise / conversion · Acquired 1,346 · Balance 12,714 F1: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value. Row 2 · 2022-06-15 · Tax withholding · Disposed 97 · Balance 12,617 F2: The referenced shares were withheld from distribution at the request of reporting person to satisfy tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-06-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-06-15 · Exercise / conversion · Disposed 1,346 · Balance 0 F3: Each RSU represents a contingent right to receive one ordinary share of the Company, GBP 1.00 par value, in accordance with the terms of the LivaNova PLC 2015 Incentive Award Plan (the Plan) and the award agreement. F4: On June 15, 2021, reporting person was granted RSUs to vest and forfeiture restrictions thereon to lapse on June 15, 2022, subject to continued service during the vesting period and the award agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value.
F2: The referenced shares were withheld from distribution at the request of reporting person to satisfy tax liability.
F3: Each RSU represents a contingent right to receive one ordinary share of the Company, GBP 1.00 par value, in accordance with the terms of the LivaNova PLC 2015 Incentive Award Plan (the Plan) and the award agreement.
F4: On June 15, 2021, reporting person was granted RSUs to vest and forfeiture restrictions thereon to lapse on June 15, 2022, subject to continued service during the vesting period and the award agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2026 Filed May 5, 2026 20:40 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantStock Option (right to buy) · Derivative | 152,783 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001213900-26-052256 · ownership.xml · derivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,783 Underlying: Common Stock · 152,783 shares Expires 2036-04-30 F1 · derivative.exercise_date: The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Read SEC document |
| October 24, 2025 Filed Oct 27, 2025 21:26 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantStock Option (right to buy) · Derivative | 42,913 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001213900-25-102680 · ownership.xml · derivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,913 Underlying: Common Stock · 42,913 shares Expires 2035-10-23 F1 · derivative.exercise_date: The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 21:25 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 2,750 | $5.62 | $15,455.00 |
DisclosureSEC source: 0001213900-24-053005 · ownership.xml · nonDerivative · entry 2 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,500 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.55 to $5.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 21:25 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 750 | $5.61 | $4,207.50 |
DisclosureSEC source: 0001213900-24-053005 · ownership.xml · nonDerivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.60 to $5.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 02:46 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $8.34 | $0.00 |
DisclosureSEC source: 0001213900-24-019220 · ownership.xml · derivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: The option award (the "Option") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and 33% on each successive one-year anniversary thereafter; provided, that the Reporting Person remains a director of the Issuer through such vesting date. Read SEC document |
| March 01, 2024 Filed Apr 6, 2024 01:45 UTC Amendment | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $8.13 | $0.00 |
DisclosureSEC source: 0001213900-24-030960 · ownership.xml · derivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-02-28 F1 · derivative.exercise_price: The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share. F2 · derivative.exercise_date: The option award (the "Option") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The shares of Common Stock underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and 33% on each successive one-year anniversary thereafter; provided, that the Reporting Person remains a director of the Issuer through such vesting date. Read SEC document |
| October 21, 2022 Filed Oct 24, 2022 14:15 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantStock Option (to acquire Common Stock) · Derivative | 100,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001213900-22-065696 · ownership.xml · derivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-10-21 F1 · derivative.exercise_date: The Reporting Person was granted 100,000 stock options. The stock options have a ten-year term and vest over two years, subject to Mr. Novak's continued service as a director, one-half vesting on the first anniversary of the grant date, and the remaining 50% vesting on the second anniversary of the grant date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:25 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 1,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-22-000067 · wf-form4_165549751888453.xml · derivative · entry 3 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,346 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company, GBP 1.00 par value, in accordance with the terms of the LivaNova PLC 2015 Incentive Award Plan (the Plan) and the award agreement. F4 · derivative.exercise_date: On June 15, 2021, reporting person was granted RSUs to vest and forfeiture restrictions thereon to lapse on June 15, 2022, subject to continued service during the vesting period and the award agreement. F4 · derivative.expiration_date: On June 15, 2021, reporting person was granted RSUs to vest and forfeiture restrictions thereon to lapse on June 15, 2022, subject to continued service during the vesting period and the award agreement. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:25 UTC | LivaNova PLC LIVN · Entity 507 | Tax withholdingOrdinary Shares | 97 | $59.94 | $5,814.18 |
DisclosureSEC source: 0001639691-22-000067 · wf-form4_165549751888453.xml · nonDerivative · entry 2 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,617 F2 · shares: The referenced shares were withheld from distribution at the request of reporting person to satisfy tax liability. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:25 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionOrdinary Shares | 1,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-22-000067 · wf-form4_165549751888453.xml · nonDerivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 22:50 UTC | LivaNova PLC LIVN · Entity 507 | SaleOrdinary Shares | 2,337 | $89.17 | $208,397.07 |
DisclosureSEC source: 0001639691-21-000113 · wf-form4_163675739365213.xml · nonDerivative · entry 2 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,368 F1 · price: Represents weighted average selling price. Securities sold through 21 separate sales on the transaction date at prices ranging from $88.89 to $89.71. The reporting person hereby undertakes to provide upon request to the SEC, the issuer or any stockholder of the issuer, the full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:50 UTC | LivaNova PLC LIVN · Entity 507 | SaleOrdinary Shares | 644 | $90.77 | $58,453.24 |
DisclosureSEC source: 0001639691-21-000113 · wf-form4_163675739365213.xml · nonDerivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,705 Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 22:59 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 2,337 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-21-000076 · wf-form4_162518031067482.xml · derivative · entry 2 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,337 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company, GBP 1.00 par value, in accordance with the terms of the LivaNova PLC 2015 Incentive Award Plan (the Plan) and the award agreement. F3 · derivative.exercise_date: On June 29, 2020, reporting person was granted RSUs to vest and forfeiture restrictions thereon to lapse on June 29, 2021, subject to continued service during the vesting period and the RSU Agreement. F3 · derivative.expiration_date: On June 29, 2020, reporting person was granted RSUs to vest and forfeiture restrictions thereon to lapse on June 29, 2021, subject to continued service during the vesting period and the RSU Agreement. F4 · balance_after: This number reflects the number of derivative securities beneficially owned following reported transaction for this specific grant. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 22:59 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionOrdinary Shares | 2,337 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-21-000076 · wf-form4_162518031067482.xml · nonDerivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 23:58 UTC | LivaNova PLC LIVN · Entity 507 | GrantRestricted Stock Units · Derivative | 1,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-21-000061 · wf-form4_162388790473086.xml · derivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,346 Underlying: Ordinary Shares · 1,346 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company, GBP 1.00 par value, in accordance with the terms of the LivaNova PLC 2015 Incentive Award Plan (the Plan) and the award agreement. F2 · derivative.exercise_date: On June 15, 2021, reporting person was granted RSUs to vest and forfeiture restrictions thereon to lapse on June 15, 2022, subject to continued service during the vesting period and the award agreement. F2 · derivative.expiration_date: On June 15, 2021, reporting person was granted RSUs to vest and forfeiture restrictions thereon to lapse on June 15, 2022, subject to continued service during the vesting period and the award agreement. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 20:33 UTC | LivaNova PLC LIVN · Entity 507 | GrantRestricted Stock Units · Derivative | 2,337 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-20-000085 · wf-form4_159363552205140.xml · derivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,337 Underlying: Ordinary Shares · 2,337 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share (Ordinary Share) of LivaNova PLC (the Company), GBP 1.00 par value, in accordance with the terms of the LivaNova PLC 2015 Incentive Award Plan (the Plan) and the award agreement. F2 · derivative.exercise_date: Reporting person was granted RSUs to vest and forfeiture restrictions thereon to lapse on June 29, 2021, subject to continued service during the vesting period and the RSU Agreement. F2 · derivative.expiration_date: Reporting person was granted RSUs to vest and forfeiture restrictions thereon to lapse on June 29, 2021, subject to continued service during the vesting period and the RSU Agreement. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 22:03 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-20-000073 · wf-form4_159286335897525.xml · derivative · entry 3 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one Ordinary Share of the Company, GBP 1.00 par value, in accordance with the terms of the LivaNova PLC 2015 Incentive Award Plan (the Plan) and the award agreement. F4 · derivative.exercise_date: Reporting person was granted RSUs to vest and forfeiture restrictions thereon to lapse on June 18 2020, subject to continued service during the vesting period and the RSU Agreement. F4 · derivative.expiration_date: Reporting person was granted RSUs to vest and forfeiture restrictions thereon to lapse on June 18 2020, subject to continued service during the vesting period and the RSU Agreement. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 22:03 UTC | LivaNova PLC LIVN · Entity 507 | Tax withholdingOrdinary Shares | 675 | $48.29 | $32,595.75 |
DisclosureSEC source: 0001639691-20-000073 · wf-form4_159286335897525.xml · nonDerivative · entry 2 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,395 F2 · shares: The referenced shares were withheld from distribution at the request of reporting person to satisfy tax liability. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 22:03 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionOrdinary Shares | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-20-000073 · wf-form4_159286335897525.xml · nonDerivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value. Read SEC document |
| June 18, 2020 Filed Nov 6, 2020 23:35 UTC Amendment | LivaNova PLC LIVN · Entity 507 | Tax withholdingOrdinary Shares | 58 | $48.29 | $2,800.82 |
DisclosureSEC source: 0001639691-20-000115 · wf-form4a_160470573768256.xml · nonDerivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,012 F1 · shares: Form 4 is being amended to revise the number of shares withheld from distribution to satisfy tax liability due to an administrative error. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 21:12 UTC | LivaNova PLC LIVN · Entity 507 | PurchaseOrdinary Shares | 1,000 | $46.71 | $46,713.00 |
DisclosureSEC source: 0001639691-20-000068 · wf-form4_159234190973538.xml · nonDerivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,570 Read SEC document |
| November 12, 2019 Filed Nov 12, 2019 16:39 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $9.36 | Not disclosed |
DisclosureSEC source: 0001209191-19-056042 · doc4.xml · derivative · entry 3 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-04-25 F3 · price: This option, which provided for vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, was accelerated and canceled in the Merger in exchange for a cash payment of $181,400.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option. F3 · derivative.exercise_date: This option, which provided for vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, was accelerated and canceled in the Merger in exchange for a cash payment of $181,400.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option. Read SEC document |
| November 12, 2019 Filed Nov 12, 2019 16:39 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | Disposition to issuerStock Option (Right to Buy) · Derivative | 33,000 | Not disclosed Strike: $7.32 | Not disclosed |
DisclosureSEC source: 0001209191-19-056042 · doc4.xml · derivative · entry 2 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,000 shares Expires 2027-05-24 F2 · price: This option, which provided for vesting over a period of three years as follows: (i) one-third of the total shares subject to the option shall vest on May 25, 2018, and (ii) 1/36th of total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of 665,940.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option. F2 · derivative.exercise_date: This option, which provided for vesting over a period of three years as follows: (i) one-third of the total shares subject to the option shall vest on May 25, 2018, and (ii) 1/36th of total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of 665,940.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option. Read SEC document |
| November 12, 2019 Filed Nov 12, 2019 16:39 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | Disposition to issuerCommon Stock | 6,901 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-056042 · doc4.xml · nonDerivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone. F1 · price: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 20:57 UTC | LivaNova PLC LIVN · Entity 507 | GrantRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-19-000105 · wf-form4_156106425222826.xml · derivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Ordinary Shares · 1,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share (Ordinary Share) of LivaNova PLC (the Company), GBP 1.00 par value, in accordance with the terms of the LivaNova PLC 2015 Incentive Award Plan (the Plan) and the award agreement. F2 · derivative.exercise_date: Reporting person was granted RSUs to vest and forfeiture restrictions thereon to lapse on June 18 2020, subject to continued service during the vesting period and the RSU Agreement. F2 · derivative.expiration_date: Reporting person was granted RSUs to vest and forfeiture restrictions thereon to lapse on June 18 2020, subject to continued service during the vesting period and the RSU Agreement. Read SEC document |
| June 15, 2019 Filed Jun 18, 2019 20:23 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 1,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-19-000087 · wf-form4_156088937380962.xml · derivative · entry 3 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,048 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one Ordinary Share of the Company, GBP 1.00 par value, in accordance with the terms of the LivaNova PLC 2015 Incentive Award Plan (the Plan) and the award agreement. F4 · derivative.exercise_date: Reporting person was granted RSUs that vested and all forfeiture restrictions thereon lapsed on June 15, 2019. F4 · derivative.expiration_date: Reporting person was granted RSUs that vested and all forfeiture restrictions thereon lapsed on June 15, 2019. Read SEC document |
| June 15, 2019 Filed Jun 18, 2019 20:23 UTC | LivaNova PLC LIVN · Entity 507 | Tax withholdingOrdinary Shares | 472 | $71.93 | $33,950.96 |
DisclosureSEC source: 0001639691-19-000087 · wf-form4_156088937380962.xml · nonDerivative · entry 2 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,570 F2 · shares: The referenced shares were withheld from distribution at the request of reporting person to satisfy tax liability. Read SEC document |
| June 15, 2019 Filed Jun 18, 2019 20:23 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionOrdinary Shares | 1,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-19-000087 · wf-form4_156088937380962.xml · nonDerivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares (Ordinary Shares) of LivaNova PLC (the Company), GBP 1.00 par value. Read SEC document |
| May 09, 2019 Filed May 10, 2019 16:34 UTC | LivaNova PLC LIVN · Entity 507 | SaleOrdinary Shares | 1,300 | $70.63 | $91,821.86 |
DisclosureSEC source: 0001639691-19-000078 · wf-form4_155750603095142.xml · nonDerivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,994 Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 16:33 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $9.36 | $0.00 |
DisclosureSEC source: 0001209191-19-026572 · doc4.xml · derivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-04-25 F1 · derivative.exercise_date: Vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 16:57 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | GrantCommon Stock | 6,901 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-008112 · doc4.xml · nonDerivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,901 F1 · shares: Represents a restricted stock unit ("RSU") award that vests 50% on each of June 30, 2019 and 25% on each of September 30, 2019 and December 31, 2019. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| December 15, 2018 Filed Dec 18, 2018 21:24 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 1,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-18-000120 · wf-form4_154516823973789.xml · derivative · entry 3 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,048 Underlying: Ordinary Shares · 1,715 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value. F3 · derivative.exercise_date: On December 15, 2017, reporting person was granted RSUs that vested and all forfeiture restrictions thereon lapsed on December 15, 2018. F3 · derivative.expiration_date: On December 15, 2017, reporting person was granted RSUs that vested and all forfeiture restrictions thereon lapsed on December 15, 2018. Read SEC document |
| December 15, 2018 Filed Dec 18, 2018 21:24 UTC | LivaNova PLC LIVN · Entity 507 | Tax withholdingOrdinary Shares | 771 | $94.45 | $72,820.95 |
DisclosureSEC source: 0001639691-18-000120 · wf-form4_154516823973789.xml · nonDerivative · entry 2 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,294 F2 · shares: The referenced shares were withheld from distribution at the request of reporting person to satisfy tax liability. Read SEC document |
| December 15, 2018 Filed Dec 18, 2018 21:24 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionOrdinary Shares | 1,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-18-000120 · wf-form4_154516823973789.xml · nonDerivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:47 UTC | LivaNova PLC LIVN · Entity 507 | SaleOrdinary Shares | 500 | $97.16 | $48,580.05 |
DisclosureSEC source: 0001639691-18-000117 · wf-form4_154474483913819.xml · nonDerivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,350 Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 16:27 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $30.11 | $0.00 |
DisclosureSEC source: 0001209191-18-038948 · doc4.xml · derivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-19 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months commencing on July 19, 2018, provided that the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| June 15, 2018 Filed Jun 18, 2018 21:13 UTC | LivaNova PLC LIVN · Entity 507 | GrantRestricted Stock Units · Derivative | 1,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-18-000067 · wf-form4_152935637043770.xml · derivative · entry 2 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,763 Underlying: Ordinary Shares · 1,048 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share (Ordinary Share) of LivaNova PLC (the Company), GBP 1.00 par value, in accordance with the terms of the LivaNova PLC 2015 Incentive Award Plan (the Plan) and the award agreement. F3 · derivative.exercise_date: Reporting person was granted RSUs that vest and all forfeiture restrictions thereon shall lapse on June 15, 2019. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement. F3 · derivative.expiration_date: Reporting person was granted RSUs that vest and all forfeiture restrictions thereon shall lapse on June 15, 2019. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 21:13 UTC | LivaNova PLC LIVN · Entity 507 | SaleOrdinary Shares | 1,000 | $104.43 | $104,431.00 |
DisclosureSEC source: 0001639691-18-000067 · wf-form4_152935637043770.xml · nonDerivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,850 F1 · price: Represents weighted average selling price. Securities sold through approximately 2 separate sales on the transaction date at prices ranging from $104.42 to $104.53. The reporting person hereby undertakes to provide upon request to the SEC, the issuer or any stockholder of the issuer, the full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 09, 2018 Filed May 11, 2018 14:07 UTC | LivaNova PLC LIVN · Entity 507 | SaleOrdinary Shares | 1,000 | $84.02 | $84,016.40 |
DisclosureSEC source: 0001639691-18-000047 · wf-form4_152604758922692.xml · nonDerivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,850 Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 21:52 UTC | LivaNova PLC LIVN · Entity 507 | GrantRestricted Stock Units · Derivative | 1,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-17-000108 · wf-form4_151372035364852.xml · derivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,715 Underlying: Common Stock · 1,715 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share ("Ordinary Share") of LivaNova PLC (the "Company") or, at the option of the Company, a cash settlement in accordance with the terms of the LivaNova PLC 2015 Incentive Award Plan. F2 · derivative.exercise_date: The reporting person was granted RSUs that vest and all forfeiture restrictions thereon shall lapse on December 15, 2018. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the LivaNova PLC 2015 Incentive Award Plan. F2 · derivative.expiration_date: The reporting person was granted RSUs that vest and all forfeiture restrictions thereon shall lapse on December 15, 2018. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the LivaNova PLC 2015 Incentive Award Plan. Read SEC document |
| November 22, 2017 Filed Nov 24, 2017 13:17 UTC | LivaNova PLC LIVN · Entity 507 | SaleCommon Stock | 2,000 | $85.77 | $171,538.60 |
DisclosureSEC source: 0001639691-17-000100 · wf-form4_151152940978626.xml · nonDerivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,850 F1 · price: Represents weighted average selling price. Securities sold through approximately 16 separate sales on the transaction date at prices ranging from $85.63 to $85.83. The reporting person hereby undertakes to provide upon request to the SEC, the issuer or any stockholder of the issuer, the full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 05, 2017 Filed Aug 8, 2017 23:52 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 3,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-17-000075 · wf-form4_150223632299871.xml · derivative · entry 3 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,327 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Reporting person was granted restricted stock units ("RSUs") settled in ordinary share of LivaNova PLC (the "Company"), GBP 1.00 par value. F3 · derivative.exercise_date: On August 5, 2016, reporting person was granted RSUs that vested and all forfeiture restrictions thereon lapsed on August 5, 2017. F3 · derivative.expiration_date: On August 5, 2016, reporting person was granted RSUs that vested and all forfeiture restrictions thereon lapsed on August 5, 2017. Read SEC document |
| August 05, 2017 Filed Aug 8, 2017 23:52 UTC | LivaNova PLC LIVN · Entity 507 | Tax withholdingCommon Stock | 1,497 | $60.41 | $90,433.77 |
DisclosureSEC source: 0001639691-17-000075 · wf-form4_150223632299871.xml · nonDerivative · entry 2 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,850 F2 · shares: The referenced shares were withheld from distribution at the request of reporting person. Such shares were forfeited and the associated value was used to offset the tax liability associated with the August 5, 2017 vesting of 3,327 RSUs. Read SEC document |
| August 05, 2017 Filed Aug 8, 2017 23:52 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionCommon Stock | 3,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-17-000075 · wf-form4_150223632299871.xml · nonDerivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Reporting person was granted restricted stock units ("RSUs") settled in ordinary share of LivaNova PLC (the "Company"), GBP 1.00 par value. Read SEC document |
| May 22, 2017 Filed May 23, 2017 21:43 UTC | LivaNova PLC LIVN · Entity 507 | SaleCommon Stock | 1,000 | $58.49 | $58,486.80 |
DisclosureSEC source: 0001639691-17-000053 · wf-form4_149557580606507.xml · nonDerivative · entry 1 Novak Alfred J · CIK 0001388862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,020 F1 · price: Represents weighted average selling price. Securities sold through approximately two (2) separate sales on the transaction date at prices ranging from $58.4861 to $58.49. The reporting person hereby undertakes to provide upon request to the SEC, the issuer or any stockholder of the issuer, the full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.